Dr. Andrew Skora brings over 15 years of experience in biologics development. He began his career as a postdoctoral researcher in the Vogelstein Lab at Johns Hopkins, where he developed MANAbody technology. Dr. Skora refined his expertise in antibody engineering at Eli Lilly, where he led teams advancing antibody therapies from discovery through IND-enabling studies. He contributed to multiple biologics for oncology and neurology and supported the development of bamlanivimab, the first anti-COVID-19 biologic authorized for use. At Viracta Therapeutics, Dr. Skora, as Senior Director, led clinical biomarker strategies.